Open AccessToxoplasmosis in organ transplant recipients: Evaluation, implication, and prevention
Author(s) -
Sumeeta Khurana,
Nitya Batra
Publication year - 2016
Publication title -
tropical parasitology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.418
H-Index - 11
eISSN - 2229-7758
pISSN - 2229-5070
DOI - 10.4103/2229-5070.190814
Subject(s) - toxoplasmosis , medicine , organ transplantation , pneumonitis , immunosuppression , immunology , encephalitis , toxoplasma gondii , chorioretinitis , pneumonia , organ dysfunction , intensive care medicine , pediatrics , transplantation , lung , sepsis , virus , antibody , ophthalmology
Toxoplasmosis in organ transplant patients can be a result of donor-transmitted infection, or reactivation of latent infection, or de novo infection. Solid organ transplants including heart, liver, kidney, pancreas and small bowel, and hematogenous stem cell transplants have been implicated in the risk of acquiring infection. In contrast to a benign course in immunocompetent individuals, the spectrum of illness is severe in transplant recipients. Clinical manifestations usually occur within the first 3 months of transplant and may present as encephalitis, pneumonitis, chorioretinitis, meningitis, and disseminated toxoplasmosis with multi-organ involvement. The diagnosis of toxoplasmosis in organ transplant patients is often difficult and is an integration of clinical, radiological, and microbiological workup. Preventive measures include pretransplant evaluation and chemoprophylaxis in view of rapidly progressing and fatal outcome of toxoplasmosis in immunocompromised individuals.